Enanta Pharmaceuticals (ENTA) Preferred Stock Liabilities (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 14 years of Preferred Stock Liabilities data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Preferred Stock Liabilities fell 2.89% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 2.89% YoY) and the FY2025 annual result came in at $1.3 million, down 2.89% from the prior year.
• Preferred Stock Liabilities was little changed at $1.3 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $1.5 million in Q1 2022 to a low of $1.3 million in Q3 2025.
• A 5-year average of $1.4 million and a median of $1.4 million in 2022 frame the typical range for Preferred Stock Liabilities.
• The widest YoY moves for Preferred Stock Liabilities: up 1.83% in 2022, down 5.51% in 2022.
• Tracing ENTA's Preferred Stock Liabilities over 5 years: stood at $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then decreased by 5.13% to $1.3 million in 2024, then retreated by 2.89% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.